ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.330
+0.020 (1.53%)
Oct 19, 2026, 10:54 AM EDT - Market open
ProQR Therapeutics Stock Forecast
PRQR's stock price has decreased by -51.66% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 9 analysts polled by S&P Global, ProQR Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $7.78. The average 1-year stock price forecast is 484.96% higher than the current stock price, while the lowest is $3.00 (+125.56%) and the highest is $10 (+651.88%).
Price Target: $7.78 (+484.96%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ProQR Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 8 | 8 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $12 → $8 | Buy | Reiterates | $12 → $8 | +501.50% | Oct 1, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $8 | Buy | Maintains | $8 | +501.50% | Oct 1, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $8 | Buy | Maintains | $8 | +501.50% | Aug 14, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $9 | Buy | Reiterates | $9 | +576.69% | Aug 14, 2026 |
| Raymond James | Raymond James | Buy Maintains $14 → $10 | Buy | Maintains | $14 → $10 | +651.88% | Jun 26, 2026 |
Financial Forecast
Revenue This Year
17.70M
from 16.35M
Increased by 8.25%
Revenue Next Year
15.87M
from 17.70M
Decreased by -10.33%
EPS This Year
-0.39
EPS Next Year
-0.40
from -0.39
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.